Cooperative behavior of fluoroquinolone combinations against Escherichia coli and Staphylococcus aureus
The effects of different combinations of ciprofloxacin (CIP) and norfloxacin (NOR) against Escherichia coli and Staphylococcus aureus were studied using checkerboard, fractional inhibitory concentration (FIC) and time-kill analysis methods. Results obtained by the checkerboard method showed that the...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Pharmaceutical Society of Japan
2017
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 15754caa a22014057a 4500 | ||
|---|---|---|---|
| 001 | PAPER-25550 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205737.0 | ||
| 008 | 190410s2017 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-85020052702 | |
| 024 | 7 | |2 cas |a ciprofloxacin, 85721-33-1; norfloxacin, 70458-96-7; Anti-Bacterial Agents; Fluoroquinolones | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a BPBLE | ||
| 100 | 1 | |a Vitorino, G.P. | |
| 245 | 1 | 0 | |a Cooperative behavior of fluoroquinolone combinations against Escherichia coli and Staphylococcus aureus |
| 260 | |b Pharmaceutical Society of Japan |c 2017 | ||
| 270 | 1 | 0 | |m Vitorino, G.P.; Departamento de Farmacia, Universidad Nacional de la Patagonia San Juan Bosco, Ciudad UniversitariaArgentina; email: gpinto@unpata.edu.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Bollenbach, T., Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution (2015) Curr. Opin. Microbiol., 27, pp. 1-9 | ||
| 504 | |a Sader, H.S., Huynh, H.K., Jones, R.N., Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against Gram-negative bacilli (2003) Diagn. Microbiol. Infect. Dis., 47, pp. 547-550 | ||
| 504 | |a Fung-Tomc, J.C., Gradelski, E., Valera, L., Huczko, E., Bonner, D.P., Synergistic activity of the novel desfluoro (6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species (2002) Int. J. Antimicrob. Agents, 20, pp. 57-60 | ||
| 504 | |a Mandal, S., Mandal, M., Pal, N.K., In vitro efficacy of ciprofloxacin alone and in combination with amoxycillin against Salmonella typhi isolates (2003) Indian J. Exp. Biol., 41, pp. 360-362 | ||
| 504 | |a Chen, Y.H., Peng, C.F., Lu, P.L., Tsai, J.J., Chen, T.P., In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa (2004) Kaohsiung J. Med. Sci., 20, pp. 261-267 | ||
| 504 | |a Al-Hasan, M.N., Wilson, J.W., Lahr, B.D., Thomsen, K.M., Eckel-Passow, J.E., Vetter, E.A., Tleyjeh, I.M., Baddour, L.M., β-Lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by Gram-negative bacilli (2009) Antimicrob. Agents Chemother., 53, pp. 1386-1394 | ||
| 504 | |a Hernández, A., Sanchez, M.B., Martinez, J.L., Quinolone resistance: Much more than predicted (2011) Front Microbiol., 2, pp. 1-6 | ||
| 504 | |a Blondeau, J.M., Fluoroquinolones: Mechanism of action, classification, and development of resistance (2004) Surv. Ophthalmol., 49, pp. S73-S78 | ||
| 504 | |a Pommier, Y., Leo, E., Zhang, H., Marchand, C.H., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs (2010) Chem. Biol., 17, pp. 421-433 | ||
| 504 | |a Hooper, D.C., Mechanisms of action of antimicrobials: Focus on fluoroquinolones (2001) Clin. Infect. Dis., 32, pp. S9-S15 | ||
| 504 | |a Fournier, B., Zhao, X., Lu, T., Drlica, K., Hooper, D., Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis (2000) Antimicrob. Agents Chemother., 44, pp. 2160-2165 | ||
| 504 | |a Fournier, B., Hooper, D., Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity (1998) Antimicrob. Agents Chemother., 42, pp. 121-128 | ||
| 504 | |a Aldred, K.J., Kerns, R.J., Osheroff, N., Mechanism of quinolone action and resistance (2014) Biochemistry, 53, pp. 1565-1574 | ||
| 504 | |a Shen, L.L., Mitscher, L.A., Sharma, P.N., O'Donnell, T.J., Chu, W.T., Cooper, C.S., Rosen, T., Pernet, A.G., Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model (1989) Biochemistry, 28, pp. 3886-3894 | ||
| 504 | |a Pali, G., Valisena, S., Ciarrocchi, G., Gatto, B., Palumbo, M., Quinolone binding to DNA is mediated by magnesium ions (1992) Proc. Natl. Acad. Sci. U.S.A., 89, pp. 9671-9675 | ||
| 504 | |a Fan, J.Y., Sun, D., Yu, H., Kerwin, S.M., Hurley, L.H., Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex (1995) J. Med. Chem., 38, pp. 408-424 | ||
| 504 | |a Llorente, B., Leclerc, F., Cedergren, R., Using SAR and QSAR analysis to model the activity and structure of the quinolone-DNA complex (1996) Bioorg. Med. Chem., 4, pp. 61-71 | ||
| 504 | |a Heddle, J.G., Barnard, F.M., Wentzell, L.M., Maxwell, A., The interaction of drugs with DNA gyrase: A model for the molecular basis of quinolone action (2000) Nucleosides Nucleotides Nucleic Acids, 19, pp. 1249-1264 | ||
| 504 | |a Pinto Vitorino, G., Sperandeo, N.R., Caira, M.R., Mazzieri, M.R., A supramolecular assembly formed by heteroassociation of ciprofloxacin and norfloxacin in the solid state: Co-crystal synthesis and characterization (2013) Cryst. Growth Des., 13, pp. 1050-1058 | ||
| 504 | |a Fabbiani, F.P., Arlin, J.B., Buth, G., Dittrich, B., Florence, A.J., Herbst-Irmer, R., Sowa, H., Intermolecular interactions, disorder and twinning in ciprofloxacin-2,2-difluoroethanol (2/3) and ciprofloxacin-water (3/14.5) (2011) Acta Crystallogr. C, 67, pp. o120-o124 | ||
| 504 | |a Mafra, L., Santos, S.M., Siegel, R., Alves, I., Almeida Paz, F.A., Dudenko, D., Spiess, H.W., Packing interactions in hydrated and anhydrous forms of the antibiotic ciprofloxacin: A solid-state NMR, X-ray diffraction, and computer simulation study (2012) J. Am. Chem. Soc., 134, pp. 71-74 | ||
| 504 | |a Becerra, M.C., Eraso, A., Albesa, I., Comparison of oxidative stress induced by ciprofloxacin and pyoverdin in bacteria and in leukocytes to evaluate toxicity (2003) Luminescence, 18, pp. 334-340 | ||
| 504 | |a Becerra, M.C., Albesa, I., Oxidative stress induced by ciprofloxacin in Staphylococcus aureus (2002) Biochem. Biophys. Res. Commun., 297, pp. 1003-1007 | ||
| 504 | |a Dwyer, D.J., Kohanski, M.A., Hayete, B., Collins, J.J., Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli (2007) Mol. Syst. Biol., 3, p. 91 | ||
| 504 | |a Breda, S.A., Jimenez-Kairuz, A.F., Manzo, R.H., Olivera, M.E., Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives (2009) Int. J. Pharm., 371, pp. 106-113 | ||
| 504 | |a Dalhoff, A., Global floroquinolone resistance epidemiology and implications for clinical use (2012) Interdiscip. Perspect. Infect. Dis., 2012, pp. 1-37 | ||
| 504 | |a Redgrave, L.S., Sutton, S.B., Webber, M.A., Piddock, L.J., Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success (2014) Trends Microbiol., 22, pp. 438-445 | ||
| 504 | |a Fish, D.N., Fluoroquinolone adverse effects and drug interactions (2001) Pharmacotherapy, 21, pp. 253S-272S | ||
| 504 | |a Leone, R., Venegoni, M., Motola, D., Moretti, U., Piazzetta, V., Cocci, A., Resi, D., Conforti, A., Adverse drug reactions related to the use of fluoroquinolone antimicrobials: An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions (2003) Drug Saf., 26, pp. 109-120 | ||
| 504 | |a Liu, H.H., Safety profile of the fluoroquinolones (2010) Focus on Levofloxacin. Drug Saf., 33, pp. 353-369 | ||
| 504 | |a Isenberg, H.D., Synergism testing: Broth microdilution checkerboard and broth macrodilution methods (1992) Clinical Microbiology Procedures Handbook, 1, pp. 5161-5181. , Anon, American Society for Microbiology, Washington | ||
| 504 | |a Guerillot, F., Carret, G., Flandrois, J.P., Mathematical model for comparison of time-killing curves (1993) Antimicrob. Agents Chemother., 37, pp. 1685-1689 | ||
| 504 | |a Ozaki, M., Segawa, J., Kitano, M., Tomii, Y., Honmura, T., Matsuda, M., Kise, M., Nishino, T., Structure-antibacterial activity and cytotoxicity relationships of thiazolo and thiazetoquinolone derivatives (1996) Biol. Pharm. Bull., 19, pp. 1457-1462 | ||
| 504 | |a Kim, J., Yoon, Y.H., Cho, I.H., Lee, J.M., Lee, K., Kim, J.E., Hong, K.H., Synthesis and antibacterial activity of a new series of quinolones with 7-substituent of [3.1.1]bicyclic amines (1996) Korean J. Med. Chem., 6, pp. 183-189 | ||
| 504 | |a Fung-Tomc, J.C., Gradelski, E., Valera, L., Kolek, B., Bonner, D.P., Comparative killing rates of fluoroquinolones and cell wall-active agents (2000) Antimicrob. Agents Chemother., 44, pp. 1377-1380 | ||
| 504 | |a Eliopoulos, G.M., Moellerig, R.C., Antimicrobial combinations (1996) Antibiotics in Laboratory Medicine, pp. 331-338. , (Lorian V ed.). Williams & Wilkins Co., U.S.A | ||
| 504 | |a Belley, A., Neesham-Grenon, E., Arhin, F.F., McKay, G.A., Parr, T.R., Jr., Moeck, G., Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus (2008) Antimicrob. Agents Chemother., 52, pp. 3820-3822 | ||
| 504 | |a Doern, C.D., When does 2 plus 2 equal 5? A review of antimicrobial synergy testing (2014) J. Clin. Microbiol., 52, pp. 4124-4128 | ||
| 504 | |a Balaji, V., Jeremiah, S.S., Baliga, P.R., Polymyxins: Antimicrobial susceptibility concerns and therapeutic options (2011) Indian J. Med. Microbiol., 29, pp. 230-242 | ||
| 504 | |a Dwyer, D., Belenky, P., Yang, J., MacDonald, I.C., Martell, J., Takahashi, N., Chan, C., Collins, J.J., Antibiotics induce redox-related physiological alterations as part of their lethality (2014) Proc. Natl. Acad. Sci. U.S.A., 111, pp. E2100-E2109 | ||
| 504 | |a Belenky, P., Ye, J.D., Porter, C.B., Cohen, N.R., Lobritz, M.A., Ferrante, T., Jain, S., Collins, J.J., Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage (2015) Cell Reports, 13, pp. 968-980 | ||
| 504 | |a Kottur, J., Nair, D.T., Reactive oxygen species play an important role in the bactericidal activity of quinolone antibiotics (2016) Angew. Chem. Int. Ed. Engl., 55, pp. 2397-2400 | ||
| 504 | |a Masadeh, M.M., Alzoubi, K.H., Al-Azzam, S.I., Khabour, O.F., Al-Buhairan, A.M., Ciprofloxacin-induced antibacterial activity is atteneuated by pretreatment with antioxidant agents (2016) Pathogens, 5, p. 28 | ||
| 504 | |a Saveta Popa, D., Kiss, B., Vlase, L., Iepure, R., Loghin, F., Different patterns of oxidative stress generation for ciprofloxacin and norfloxacin (2007) Toxicol. Lett., 172 S, p. S25 | ||
| 504 | |a Barnes, A.I., Herrero, I., Albesa, I., New aspect of the synergistic antibacterial action of ampicillin and gentamicin (2005) Int. J. Antimicrob. Agents, 26, pp. 146-151 | ||
| 504 | |a Molina-Quiroz, R.C., Loyola, D., Muioz-Villagrán, C., Quatrini, R., Vásquez, C., Pirez-Donoso, J., DNA, cell wall and general oxidative damage underlie the tellurite/cefotaxime synergistic effect in Escherichia coli (2013) PLOS ONE, 8, p. e79499 | ||
| 504 | |a Smirnova, G.V., Tyulenev, A., Muzyka, N., Peters, M., Oktyabrsky, O., Ciprofloxacin provokes SOS-dependent changes in respiration and membrane potential and causes alterations in the redox status of Escherichia coli (2017) Res. Microbiol., 168, pp. 64-73 | ||
| 520 | 3 | |a The effects of different combinations of ciprofloxacin (CIP) and norfloxacin (NOR) against Escherichia coli and Staphylococcus aureus were studied using checkerboard, fractional inhibitory concentration (FIC) and time-kill analysis methods. Results obtained by the checkerboard method showed that the more effectives combinations against Escherichia coli were 0.0009 μg/mL CIP0.0312 μg/mL NOR and 0.0037 μg/mL CIP0.0075 μg/mL NOR with a FIC index of 0.62. For Staphylococcus aureus, the combination of 0.0625 μg/mL CIP0.2500 μg/mL NOR showed a synergistic effect, with a FIC index of 0.50. The results of the time-kill method demonstrated either indifference or additivity of the combinations 0.0009 μg/mL CIP+0.0312 μg/mL NOR, 0.0018 μg/mL CIP+0.0312 μg/mL NOR, 0.0037 μg/mL CIP+0.0075 μg/mL NOR and 0.0037 μg/mL CIP+0.0156 μg/mL NOR at 24 h against E. coli. The combination 0.0037 μg/mL CIP+0.0312 μg/mL NOR showed synergistic activity. All the analyzed combinations evidenced bactericidal effects at 4 h. The combinations 0.0625 μg/mL CIP+0.2500 μg/mL NOR and 0.0625 μg/mL CIP+0.0625 μg/mL NOR showed indifference or additivity against S. aureus. None of them generated bactericidal effect at 4 h. Moreover, this last equimolecular combination (equivalent to 1/4 minimum inhibitory concentration (MIC) CIP+1/16 MIC NOR) generated higher reduction of nitro blue tetrazolium than drugs alone. By another way, combinations not equimolecular of CIP and NOR assayed, generated less levels of reactive oxygen species (ROS) than the components alone. © 2017 The Pharmaceutical Society of Japan. |l eng | |
| 593 | |a Departamento de Farmacia, Universidad Nacional de la Patagonia San Juan Bosco, Ciudad Universitaria, Comodoro Rivadavia, Chubut, 9000, Argentina | ||
| 593 | |a Departamento de Farmacia, IMBIV-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba, 5000, Argentina | ||
| 593 | |a Departamento de Química, Facultad de Ciencias Naturales, Universidad Nacional de la Patagonia San Juan Bosco, Ciudad Universitaria, Comodoro Rivadavia, Chubut, 9000, Argentina | ||
| 593 | |a Department of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa | ||
| 690 | 1 | 0 | |a CIPROFLOXACIN |
| 690 | 1 | 0 | |a COMBINATION |
| 690 | 1 | 0 | |a COOPERATIVE BEHAVIOR |
| 690 | 1 | 0 | |a FLUOROQUINOLONE |
| 690 | 1 | 0 | |a NORFLOXACIN |
| 690 | 1 | 0 | |a SINERGISTIC EFFECT |
| 690 | 1 | 0 | |a CIPROFLOXACIN |
| 690 | 1 | 0 | |a NORFLOXACIN |
| 690 | 1 | 0 | |a QUINOLINE DERIVED ANTIINFECTIVE AGENT |
| 690 | 1 | 0 | |a REACTIVE OXYGEN METABOLITE |
| 690 | 1 | 0 | |a ANTIINFECTIVE AGENT |
| 690 | 1 | 0 | |a QUINOLONE DERIVATIVE |
| 690 | 1 | 0 | |a ANTIBACTERIAL ACTIVITY |
| 690 | 1 | 0 | |a ANTIBIOTIC SENSITIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DRUG EFFECT |
| 690 | 1 | 0 | |a DRUG EFFICACY |
| 690 | 1 | 0 | |a DRUG MECHANISM |
| 690 | 1 | 0 | |a DRUG POTENTIATION |
| 690 | 1 | 0 | |a ESCHERICHIA COLI |
| 690 | 1 | 0 | |a FRACTIONAL INHIBITORY CONCENTRATION INDEX |
| 690 | 1 | 0 | |a IN VITRO STUDY |
| 690 | 1 | 0 | |a MINIMUM INHIBITORY CONCENTRATION |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PROTEIN BLOOD LEVEL |
| 690 | 1 | 0 | |a STAPHYLOCOCCUS AUREUS |
| 690 | 1 | 0 | |a DRUG EFFECTS |
| 690 | 1 | 0 | |a ESCHERICHIA COLI |
| 690 | 1 | 0 | |a GROWTH, DEVELOPMENT AND AGING |
| 690 | 1 | 0 | |a MICROBIAL SENSITIVITY TEST |
| 690 | 1 | 0 | |a STAPHYLOCOCCUS AUREUS |
| 690 | 1 | 0 | |a ANTI-BACTERIAL AGENTS |
| 690 | 1 | 0 | |a DRUG SYNERGISM |
| 690 | 1 | 0 | |a ESCHERICHIA COLI |
| 690 | 1 | 0 | |a FLUOROQUINOLONES |
| 690 | 1 | 0 | |a MICROBIAL SENSITIVITY TESTS |
| 690 | 1 | 0 | |a STAPHYLOCOCCUS AUREUS |
| 700 | 1 | |a Becerra, M.C. | |
| 700 | 1 | |a Barrera, G.D. | |
| 700 | 1 | |a Caira, M.R. | |
| 700 | 1 | |a Mazzieri, M.R. | |
| 773 | 0 | |d Pharmaceutical Society of Japan, 2017 |g v. 40 |h pp. 758-764 |k n. 6 |p Biol. Pharm. Bull. |x 09186158 |t Biological and Pharmaceutical Bulletin | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020052702&doi=10.1248%2fbpb.b16-00616&partnerID=40&md5=914b80c8353e3862f11fc4875873877d |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1248/bpb.b16-00616 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_09186158_v40_n6_p758_Vitorino |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09186158_v40_n6_p758_Vitorino |y Registro en la Biblioteca Digital |
| 961 | |a paper_09186158_v40_n6_p758_Vitorino |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 86503 | ||